The Europe medical cannabis market is projected to grow from US$ 492.1 million in 2021 to US$ 13,801.0 million by 2028, expanding at a remarkable CAGR of 61.1% from 2022 to 2028. This growth is primarily driven by increasing research on the therapeutic applications of cannabis and growing government support through funding and policy initiatives. However, the persistent illegal use of cannabis as a recreational drug remains a challenge to market expansion.
?Download Full PDF Sample Copy of Market Report @
https://www.businessmarketinsights.com/sample/TIPRE00018766
While a growing number of European countries are enacting medical cannabis legislation, it remains uncommon for governments to actively encourage healthcare professionals to gain formal education on cannabis-based treatments. A notable exception occurred in 2016 when cannabis experts were invited to North Macedonia to train local healthcare providers on the clinical use of medical cannabis. The training program, held in Skopje, was backed and funded by the Macedonian Ministry of Health.
North Macedonia presents unique opportunities for medical cannabis integration, particularly as its healthcare system continues to evolve and modernize. Local specialists are now authorized to prescribe medical cannabis, and efforts are underway to expand medical cannabis education through structured training programs for doctors. With strong collaboration between cannabis advocates and local authorities, public perception in the region has shifted significantly in favor of medical marijuana.
This growing momentum in North Macedonia highlights a broader call for the European Commission and EU Member States to address regulatory, financial, and cultural barriers that hinder scientific cannabis research—and to promote further investment in this transformative area of healthcare.
Europe Medical Cannabis Strategic Insights
Strategic insights for the Europe Medical Cannabis provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
key company profiles
· Organigram Holdings Inc
- Aurora Cannabis Inc
- Cannabis Science, Inc
- Canopy Growth Corporation
- Medical Marijuana Inc
- VIVO Cannabis Inc
- Tikun Olam
- Tilray
- The Cronos Group
- Canvory
Regional Insights: Europe Medical Cannabis Market
The geographic scope of the Europe medical cannabis market encompasses the specific regions where businesses operate and compete. Success in this market depends on a deep understanding of regional differences, including consumer preferences, economic conditions, and regulatory frameworks. For example, variations in healthcare policies, public attitudes toward cannabis use, and prescribing practices require localized strategies. Companies can enhance their market presence by identifying underserved regions and tailoring their products and services to meet unique local needs. A well-defined regional focus enables more efficient allocation of resources, development of targeted marketing efforts, and stronger positioning against local competitors—ultimately driving sustainable growth across Europe.
Government funding continues to spur research into the therapeutic potential of cannabis for COVID-19. In September 2020, EXMceuticals Inc. secured roughly US $353,000 (EUR 302,000) from the European Union and the Portuguese government for its BioBlockCOVID project, which is developing natural biocidal formulations that target key viral molecules. Such investments are expected to accelerate innovation and, consequently, fuel rapid growth in the medical cannabis market throughout the forecast period.
Country Analysis – Germany
Medical cannabis prescriptions were legalised in Germany in March 2017, and an expanding range of cannabis-based medicines is now available through pharmacies. Federal Ministry of Health data show that pharmacy sales rose from 33.8 kg in the first half of 2015 to 61.8 kg in the same period of 2016. Clinical research is also gaining momentum: Sativex, approved in 2011 as an add-on therapy for moderate-to-severe multiple-sclerosis-related spasticity, has proven cost-effective in German studies. Reflecting rising demand, the Federal Institute for Drugs and Medical Devices (BfArM) authorised domestic cultivation of up to 10,400 kg of medical cannabis over four years starting in July 2018. Increased local production and sustained government support are therefore pivotal drivers of market expansion.
Sources: Centers for Disease Control and Prevention (CDC); National Library of Medicine; Prohibition Partners; State Agency for Medical Cannabis (SAKL); Worldometer.
About Us:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Défense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
Author's Bio
Akshay
Senior Market Research Expert at Business Market Insights
